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Abstract: Four ligands based on Chromene derivatives have been docked into integrase of prototype 
foamy virus, which has high structural similarity with that of HIV-1 integrase. The Autodock Vina 
(Vina) software was used for this purpose. The docking scores for the derivatives are -7.3 kcal/mol, 
-7.5 kcal/mol, -6.9 kcal/mol, and -7.2 kcal/mol, respectively, which are comparable with that for 
Raltegravir (-10.7 kcal/mol). The docking results provide a detailed evidence for the interactions of 
four Chromene derivatives. The results may lead to the design and development of new drug 
candidates against AIDS. 
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The main reason of the acquired 
immunodeficiency syndrome (AIDS) is the 
human immunodeficiency virus type 1 (HIV-
1). This is a progressive, sluggish and 
degenerative disease of the human immune 
system. HIV-1 belongs to the retrovirus 
family, which is classified as a lentivirus (1). 
The HIV replication cycle involves the 
integration of viral DNA into the host 
chromosome, which is an essential process 
conducted by the viral integrase (IN) protein. 
This protein, together with reverse 
transcriptase and protease, is one of three 
enzymes encoded by HIV (2). The current 
antiviral therapy for treatment of AIDS 
includes a combination therapy with reverse 
transcriptase and protease inhibitors with a 
potential therapeutic capability (3). The 
integrase is a 32 kDa enzyme composed of 
three functional domains (catalytic core 
domain, an N-terminal domain and a less 
conserved C-terminal domain) (4,5). It does 
not have sequence homologue or an 
equivalent counterpart in the human host cell. 
Therefore, this makes the protein an attractive 
drug target (6). There are few integrase 
inhibitors introduced as promising drug 
candidates for the treatment of AIDS after the 
authorization of Raltegravir (7). Despite the 
effective activity of Raltegravir and several 
other inhibitors against anti-HIV integrase 
they possess adverse influences on prolonged 
usage and develop drug resistance. Thus, 
there is an urgent requirement to investigate 
new and potential chemical scaffolds for the 
treatment of AIDS.  
 
Diketo acids (DKA) possess a metal-chelating 
function and they can simultaneously 
coordinate two divalent metal ions. Therefore, 
they are considered as potent inhibiting 
proteins which bear divalent metals which are 
involved in the hydrolysis of endonucleolytic 
phosphodiesters (8-9). Raltegravir is the first 
efficient anti-HIV drug targeting HIV-1 IN, 
which is classified as a diketo acid-based 
derivative. FDA approved it in October 2007. 
Besides, Elvitegravir is a monoketo acid 
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derivative which has two functional groups 
with only one metal ion binding site. It is 
identified as a second integrase inhibitor 







Figure 1. Structures of ligands used for molecular docking. (The atoms in interaction with protein 
or DNA labelled by number in structure file.). 
 
The computational methods have occupied a 
significant place in drug discovery. These 
methods are collectively termed 
pharmacoinformatics. They include virtual 
screening, structure activity relationship 
(SAR), pharmacophore and molecular 
docking. These approaches have widely been 
employed in the pharmaceutical industry for 
identification and optimization including 
several groups who have identified IN 
inhibitors for HIV therapy (12–17). The 
current research involves exploring the 
binding choice of the inhibitory molecules of 
HIV IN according to virtual screening and 
space modelling study together with molecular 
docking. Chromene derivatives (Figure 1), 
(L01), (L02), (L03) and (L04) were used as 
ligands. The structure of the HIV-1 IN has not 
yet been experimentally determined. 
Nevertheless, it is known that INs have a high 
level of conservation especially within their 
active sites (6, 8, 9, 17) (Calculated catalytic 
core residues identity between 1BL3.pdb and 
3OYA.pdb with Chimera is 25%) and the 
catalytic triad DDE motif which interacts with 
both target and viral DNA. Recently an X-ray 
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structure of prototype foamy virus (PFV) IN 
has been resolved and thus it can provide a 
basis for structural explorations of HIV INs 
(18, 19). HIV-1 lacks only Ser217 residue in 
the immediate vicinity of the catalytic 
carboxylates of PFV IN. Nevertheless, this 
residue is not directly involved in the 
interaction of IN with integrase strand transfer 
inhibitors (INSTIs) (6). 
 
MATERIAL AND METHOD 
 
Preparing of Receptor Structure 
We obtained the crystallographic structure of 
full-length (3OYA.pdb) PFV Integrase from the 
Protein Data Bank (www.rcsb.org). This 
structure includes a DNA fragment and 
Raltegravir. After removing all ligands and 
water molecules from crystal structure, 
receptor and ligand files were separately 
saved by DS Visualizer software. MGL Tools 
(Version 1.5.7rc1) was used for creating pdbqt 
files of receptor and ligands needed for 
docking with Autodock Vina (Vina) (Version 
1.1.2).  
 
Preparing of Ligand Structures 
2D structures of ligands were drawn with 
Chemaxon Marvin Sketch program and also 
saved as 3D structure file in mol2 file format. 
Structures were then optimized with semi-
empirical PM6 method with Gaussian 09 (18) 
program. Charges were derived by 
antechamber module of AMBER 14 (19) suite 
software. Ptbqt files of ligands were prepared 
with MGL Tools by keeping charges obtained 
from the antechamber.  
 
Docking Method and Method Validation 
Autodock Vina uses an efficient quasi-Newton 
and Broyden-Fletcher-Goldfarb-Shanno 
(BFGS) methods for local optimization (20). 
Ligands were docked to binding site cavity 
using x=-38.7 Å, y=29.9 Å, and z=-20.2 Å 
Cartesian coordinates which take catalytic site 
in. The grid box dimensions used for search 
space were 28 Å x 28 Å x 28 Å. Docking 
calculations were performed with 
exhaustiveness option of 8 (average accuracy) 
and an energy range of 3. The Vina gives 
docking scores as predicted inhibition 
constants (Ki), which is derived from Gibbs 
free energy of binding calculated by following 
equations, 
𝛥𝐺 = −𝑅𝑇(𝑙𝑛𝐾𝑖)  Eq. 1 
𝐾𝑖 = 𝑒
−𝛥𝐺
𝑅𝑇   Eq. 2 
where R (gas constant) is 1.98 cal/mol.K, and 
T is 298.15 K. 
 
Validation of docking method was performed 
by re-docking Raltegravir to the crystal 
structure. Binding mode of Raltegravir to the 
protein structure is shown in Fig. 2 which 
shows the ligand is located in a similar mode 
with its original location.  
 
Figure 2. Validation of docking with Autodock Vina (pink: original coordinates, green: docking 
mode of Raltegravir with Vina) 
 





RESULTS AND DISCUSSION 
 
On one hand, the prediction of some 
properties of molecules is important for their 
consideration as drug candidates. These are 
defined by the Lipinski’s rules. (21). Analyses 
demonstrate that all the ligands follow the 
Lipinski’s rule of five and they show moderate 
water solubility (Table 1) 
 
Table 1. Molecular properties of ligands according to Lipinski’s rules. 








L01 298.29 1 5 2.81 82.93 
L02 300.11 1 5 2.61 80.51 
L03 358.34 1 7 2.83 95.91 
L04 358.34 1 7 2.79 95.91 
 
Four ligands were successfully docked to PFV 
IN by Autodock Vina. Raltegravir gave the best 
docking score which was used for validation of 
docking method with a score of -10.7 
kcal/mol. L01, L02, L03, and L04 have a 
docking score of -7.3 kcal/mol, -7.5 kcal/mol, 
-6.9 kcal/mol, and -7.2 kcal/mol, respectively. 
The ligands have quite similar docking scores 
with comparable magnitude to that of 
Raltegravir. 
 
X-ray structure of PNV IN (22) demonstrates 
that Tyr212 (corresponding Tyr 143 in HIV-1 
Integrase) is involved in a face-to-face π–π 
stacked interaction with the oxadiazole ring of 
Raltegravir. Raltegravir also forms two 
hydrogen bonds with Tyr212, and two water 
molecules coordinated with the metal ions. 
The other important interaction between 
Raltegravir and receptor (protein and DNA) 
involves π–π stacking with DC16 (DNA 
cytosine), DA17 (DNA adenine), Gln215 and 
Pro214. The electrostatic interaction with both 
Mg ions is of course one of the most significant 
interactions (Figure 3). 
 
Figure 3. Interaction mode of RAL with IN obtained from docking results. 
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All the ligands are placed in catalytic center of 
integrase and they all interact with both Mg 
ions. In L01, O11 and O20 atoms form 
electrostatic interactions with Mg ions while O5 
atom forms a hydrogen bond with HN atom of 
DA17. Chromene ring of L01 also forms π-
anion, π/CH interaction with Glu221, and 
Pro214, respectively (Figure 4). L02, which 
differs from L01 by lacking the double bond 
between C8 and C9 atoms of chromene, has a 













Figure 5. Interaction mode of L02 with IN obtained from docking results. 
 
Unlike other three ligands, L03 forms 
electrostatic interaction with only Mg 397 
atom. The distances between ligand oxygen 
atoms and Mg atoms are shown in Table 2. The 
other interactions of L03 with the receptor 
include the π-π stacking between chromene 
and DA17 and π/CH interactions between 
chromene and Pro214 (Figure 6). On the other 
hand, L04 ligand has two hydrogen bonds, one 
is between O24 in the ligand and the amide NH 
of Tyr212 and the other is between H6 in the 
ligand and OE1 of Glu221 residue. Besides, 
there are electrostatic interactions of oxygen 
atoms in the ligand with Mg atoms and π/CH 
interaction with Pro214 residue (Figure 7). 
 
 















Figure 7. Interaction mode of L04 with IN obtained from docking results. 
 
The binding role and importance of metal ions 
which are contained in the enzyme is well 
known (23). Table 2 details the distances 
between Mg2+ ions and related ligand atoms. 
Hereunder, except L03-O24/Mg396 ligands 
have an acceptable interaction distance with 
Mg2+ ions and while all other ligands make an 
interaction with both Mg2+ ions by one oxygen 
atom, L03 is in interaction with one Mg2+ ion 
per oxygen atom (L03-O11/Mg397, L03-
O24/Mg397). L03-O24/Mg396 interaction is 
weak (4.03 Å) when comparing with other 
ligands’ equivalent oxygen atoms-Mg 
interactions.  
 
Table 2. Interaction distances between the oxygen atoms in the ligands with Mg atoms. 
Ligand Atoms MG396 MG397 
L01-O11 2.51 Å 2.60 Å 
L01-O20 2.41 Å - 
L02-O11 2.43 Å 2.66 Å 
L02-O20 2.47 Å - 
L03-O11 - 2.75 Å 
L03-O24 4.03 Å 2.76 Å 
L04-O6 - 2.27 Å 
L04-O11 2.98 Å 2.26 Å 
 






The docking results provide a detailed 
evidence for the interactions of four Chromene 
derivatives. Docking scores and interactions of 
ligands with catalytic core residues and Mg 
ions encourage hope for a new ligand group in 
HIV-1 drug design studies. Also, we note that 
these ligands need some improvements by 
adding or removing some fragments. This 
information may be used for the design and 
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